Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNTech: We Could Produce New COVID Variant Vaccine In Six Weeks, If Needed

Confident That Existing Vaccine Still Works

Executive Summary

The speed of the new messenger RNA platforms could once again come to the rescue, but fortunately the existing vaccines should remain effective against the emerging strain.

You may also be interested in...



COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.

Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains

The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.

UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts

UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel